Niagen Bioscience (NAGE) Operating Expenses (2010 - 2026)

Niagen Bioscience (NAGE) has 17 years of Operating Expenses data on file, last reported at $18.4 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 26.38% year-over-year to $18.4 million in Q1 2026; TTM through Mar 2026 was $70.8 million, a 30.46% increase from a year earlier, with the FY2025 full-year figure at $66.9 million, up 24.23% from the prior year.
• Operating Expenses for Q1 2026 stood at $18.4 million, up from $17.6 million in the prior quarter.
• Over the last five years, Operating Expenses for NAGE reached as high as $18.4 million in Q1 2026 and fell as low as $11.1 million in Q4 2024.
• Historically, Operating Expenses has averaged $15.1 million across 5 years, with a median of $14.6 million in 2024.
• Across the five-year window, Operating Expenses tumbled 31.65% in 2022 and jumped 58.92% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $13.5 million in 2022, then decreased by 2.64% to $13.1 million in 2023, then declined by 15.41% to $11.1 million in 2024, then surged by 58.92% to $17.6 million in 2025, then grew by 4.44% to $18.4 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $18.4 million in Q1 2026, $17.6 million in Q4 2025, and $17.7 million in Q3 2025.